Avapritinib for PDGFRA Exon 18-Mutated GIST: Michael Heinrich, MD

Up to 10% of patients with gastrointestinal stromal tumor (GIST) harbor platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, which have been linked to resistance to standard GIST therapies. The FDA's recent approval of avapritinib (AyvakitTM, Blueprint Medicines) for adults with unresectable or metastatic GIST with PDGFRA exon 18 mutations has given these patients a highly promising treatment option. In this interview, Michael C. Heinrich, MD, lead investigator of the phase ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.